The Royalty Factory Behind the Barbell
Porter Stansberry’s Ignition Point pitch is framed as a barbell of royalty “tollbooth” names providing ballast alongside speculative drug developers. Ligand Pharmaceuticals (LGND) is one of the tollbooth companies that appears in the context of the pitch, though it is not a confirmed formal pick. Its model is worth understanding on its own, because Ligand is one of the clearest pure examples of a royalty business in biotech.
Ligand does not bet on a single blockbuster. It owns a portfolio of technologies and licenses them out to other drugmakers, then collects royalties, milestone payments, and licensing fees as those partners advance drugs through trials and onto the market.
Captisol Is the Anchor
The anchor of Ligand’s business is Captisol, a chemically modified sugar used to make poorly soluble drugs injectable. Many medicines that would otherwise clump or fail to dissolve in the body can be formulated with Captisol, which is why it shows up in a long list of approved products, including some well-known antiviral and oncology drugs.
Every time one of those drugs is manufactured and sold, Ligand earns a royalty tied to the Captisol used in it. That is a genuine tollbooth: Ligand does not run the clinical trials, does not build the manufacturing plants, and does not carry the regulatory risk for the final drug. It supplies a formulation ingredient and shares in the resulting sales.
Royalties and Licensing, Not Trials
The licensing side works the same way. Ligand owns a library of technology platforms covering things like drug delivery and formulation, and it partners with other companies to apply them. In return it takes an upfront fee, milestone payments if the drug hits development checkpoints, and a royalty on any commercial sales.
That structure insulates Ligand from the single-trial blowups that sink ordinary biotechs. When Novartis’s pelacarsen failed its cardiovascular endpoint on September 4, 2026, it was a catastrophe for one program but barely a footnote to a company spread across dozens of partnered drugs. That is precisely the ballast Porter is reaching for with the tollbooth half of his barbell, which he explains in his broader Royalty Riches teardown.
The Trade-Off
The honest caveat is growth. A royalty model is durable, but it does not compound like a company that owns a successful drug outright. Ligand’s revenue rises with its partners’ success, which is slower and less dramatic than a developer whose one candidate finally works. It also depends on the continued health of the products that carry Captisol, some of which will lose exclusivity over time.
Ligand has to keep refreshing the portfolio, signing new partners and new drugs to replace the royalties that mature. That is a different skill than drug discovery, and it is closer to the aggregator model we profile in our Royalty Pharma piece.
The Bottom Line
Ligand is a clean way to see the tollbooth thesis in action. It turns a formulation ingredient and a licensing library into a stream of royalties that survive the failure of any single drug. Whether that makes it a buy depends on whether the price fairly reflects a slower, steadier growth profile, but the model itself is exactly the kind of ballast Porter’s barbell is built around.
The Captisol Moat
Captisol is a hard ingredient to displace. It is not the active drug; it is the excipient that makes the drug injectable, and once a drug is approved with a specific formulation, changing that formulation is expensive and slow. A drugmaker that has spent years getting a product approved with Captisol is not going to swap it out lightly.
That stickiness is the real moat. Ligand’s royalty does not depend on the underlying drug being first in class; it depends on the drug continuing to sell, and approved products tend to keep selling for years. Even when the underlying molecule eventually faces generic competition, the formulation and the Captisol supply often remain in place longer than the patent on the molecule itself.
The result is a stream of royalties with unusually long tails. Ligand collects on drugs it helped formulate for a decade or more, and that duration is what turns a small percentage royalty into a meaningful annuity. It is the same compounding logic behind every tollbooth, applied to the chemistry that makes a drug injectable.
The flip side is that Ligand must keep finding new molecules to formulate. Captisol is durable, but it is not a growth engine on its own, so the company’s long-run value leans on the licensing side of the business signing new partners year after year. That pipeline of new deals is the number to watch.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.